Saturday, March 2, 2024

CATEGORY

Merck (MSD)

Treatment for Cervical Cancer KEYTRUDA, Approved by FDA, Combined with Chemoradiotherapy

Merck, known as MSD outside the United States and Canada, has received FDA approval for its anti-PD-1 therapy, KEYTRUDA, in combination with chemoradiotherapy (CRT)...

FDA Awards Priority Review to Daiichi Sankyo-Merck’s Treatment for Lung Cancer

The US FDA has given priority review to Daiichi Sankyo and Merck’s application for patritumab deruxtecan, a potential therapy for non-small cell lung cancer...

Merck’s V116 Pneumococcal Vaccine Granted Priority Review by FDA for Adult Population

Merck recently received acknowledgment from the US Food and Drug Administration (FDA) regarding the priority review acceptance of its Biologics License Application (BLA) for...

KEYTRUDA® + Chemotherapy Approved for Gastrointestinal Cancers

Merck, known as MSD outside the US and Canada, secured two new KEYTRUDA approvals in the EU for gastrointestinal cancers: KEYTRUDA combined with fluoropyrimidine-platinum...

Merck’s KEYTRUDA® Combo FDA Approved for Gastric Cancer

Merck, known as MSD outside the US and Canada, has gained FDA approval for KEYTRUDA, its anti-PD-1 therapy, alongside chemotherapy as the first-line treatment...

Merck’s Involvement in the Jefferies London Healthcare Conference

Merck, also known as MSD outside the United States and Canada, has announced the participation of Caroline Litchfield, the executive vice president, and chief...

FDA Grants Keytruda Approval for Biliary Tract Cancer, Challenging Imfinzi’s Reign

In a significant development, the FDA has approved MSD's PD-1 inhibitor Keytruda (pembrolizumab) for the treatment of locally advanced unresectable or metastatic biliary tract...

Merck’s President, Jannie Oosthuizen, to Address UBS BioPharma Conference

Merck, also known as MSD outside the United States and Canada, has made a significant announcement regarding its participation in the upcoming UBS BioPharma...

FDA Approves Keytruda as First Immunotherapy for Advanced Biliary Tract Cancer

The FDA has approved MSD's (Merck) PD-1 inhibitor Keytruda (pembrolizumab) for the treatment of locally advanced unresectable or metastatic biliary tract cancer (BTC). This...

FDA Accepts Merck’s BLA for Sotatercept in Groundbreaking Pulmonary Arterial Hypertension Treatment

The US Food and Drug Administration (FDA) has given the green light to Merck's (known as MSD outside the US) biologics license application (BLA)...

Latest news

Sticky Image